Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
The lab testing company made the announcement as the virus has rapidly spread across the world, and the administration's response has received widespread criticism. LabCorp also announced the availability of its test.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The companies said the deal, financial terms of which were not disclosed, would enable expansion of next-generation sequencing capabilities in rare diseases.